Immatics Biotechnologies GmbH
11
1
2
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
18.2%
2 terminated/withdrawn out of 11 trials
77.8%
-8.7% vs industry average
9%
1 trials in Phase 3/4
0%
0 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor
Role: lead
IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors
Role: lead
IMA970A Plus CV8102 in Very Early, Early and Intermediate Stage Hepatocellular Carcinoma Patients
Role: collaborator
GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients
Role: lead
F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma
Role: collaborator
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
Role: lead
Phase I/II Trial of IMA950 Multi-peptide Vaccine Plus Poly-ICLC in Glioblastoma
Role: collaborator
Vaccine Therapy, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Role: collaborator
Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma
Role: lead
IMA910 Plus GM-CSF With Low-dose Cyclophosphamide Pre-treatment in Advanced Colorectal Carcinoma Patients Following a Successful 12 Week First-line Treatment With Oxaliplatin-based Chemotherapy (IMA910-101)
Role: lead
IMA901 in Advanced Renal Cell Carcinoma Patients With Measurable Disease
Role: lead
All 11 trials loaded